Cytokinetics (CYTK) FCF Margin (2010 - 2026)
Cytokinetics (CYTK) posted quarterly FCF Margin of 782.38% for Q1 2026, up 791179.0% year-over-year from N/an in Q1 2025, and up 15.99% quarter-over-quarter from 931.35% in Q4 2025.
Powered by 
Analysis
Cytokinetics (CYTK) FCF Margin (2010 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported FCF Margin for 17 consecutive years, with 782.38% the latest figure, recorded in Q1 2026.
- In Q1 2026, FCF Margin rose 791179.0% year-over-year to 782.38%; the TTM figure through Mar 2026 stood at 518.79% (up 183509.0% YoY), while the FY2025 annual figure was 607.47%, up 205410.0% from the prior year.
- FCF Margin rose to 782.38% in Q1 2026 per CYTK's latest filing, from 931.35% in the prior quarter.
- Across five years, FCF Margin topped out at 102.66% in Q2 2022 and bottomed at 39912.05% in Q2 2024.
- Historically, FCF Margin has averaged 8947.02% across 5 years, with a median of 4347.97% in 2023.
- Annual changes were most pronounced in 2024 — FCF Margin slumped 2591758 bps — and 2025, when it soared 3972423 bps.
- Cytokinetics' FCF Margin stood at 5181.14% in 2022, then increased by 16 bps to 4347.97% in 2023, then surged by 90 bps to 456.35% in 2024, then slumped by 104 bps to 931.35% in 2025, then grew by 16 bps to 782.38% in 2026.
- Business Quant data shows CYTK's FCF Margin at 782.38% in Q1 2026, 931.35% in Q4 2025, and 5514.62% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Cytokinetics | 9.63 Bn | 8.46 Bn | 25.89 Mn | -573.41% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -573.41% |
| Mar 31, 2026 | -782.38% |
| Dec 31, 2025 | -834.99% |
| Sep 30, 2025 | -6,038.27% |
| Jun 30, 2025 | -198.27% |
| Mar 31, 2025 | -8,694.17% |
| Dec 31, 2024 | -445.73% |
| Sep 30, 2024 | -22,073.65% |
| Jun 30, 2024 | -39,949.40% |
| Mar 31, 2024 | -15,719.88% |
| Dec 31, 2023 | -4,432.66% |
| Sep 30, 2023 | -25,509.26% |
| Jun 30, 2023 | -14,123.53% |
| Mar 31, 2023 | -2,661.15% |
| Dec 31, 2022 | -5,181.14% |
| Sep 30, 2022 | -3,469.15% |
| Jun 30, 2022 | -105.17% |
| Mar 31, 2022 | -2,494.77% |
| Dec 31, 2021 | -112.39% |
| Sep 30, 2021 | -1,001.84% |